Bioneer Past Earnings Performance
Past criteria checks 0/6
Bioneer has been growing earnings at an average annual rate of 9.3%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 31.8% per year.
Key information
9.3%
Earnings growth rate
9.9%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 31.8% |
| Return on equity | -2.9% |
| Net Margin | -4.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Lacklustre Performance Is Driving Bioneer Corporation's (KOSDAQ:064550) Low P/S
Mar 06
Bioneer (KOSDAQ:064550) Seems To Use Debt Quite Sensibly
Mar 25Bioneer Corporation's (KOSDAQ:064550) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 15Investors Who Bought Bioneer (KOSDAQ:064550) Shares A Year Ago Are Now Up 166%
Jan 20
Is Bioneer (KOSDAQ:064550) A Risky Investment?
Dec 24Here's Why We Think Bioneer's (KOSDAQ:064550) Statutory Earnings Might Be Conservative
Nov 28Revenue & Expenses BreakdownBeta
How Bioneer makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 263,237 | -10,587 | 181,746 | 15,031 |
| 30 Sep 23 | 248,909 | -3,698 | 170,419 | 13,750 |
| 30 Jun 23 | 229,759 | 4,476 | 153,110 | 13,447 |
| 31 Mar 23 | 212,970 | 2,917 | 140,471 | 16,275 |
| 31 Dec 22 | 218,394 | 12,077 | 134,223 | 16,751 |
| 30 Sep 22 | 224,372 | 23,194 | 129,713 | 17,881 |
| 30 Jun 22 | 233,768 | 4,807 | 142,082 | 18,640 |
| 31 Mar 22 | 235,316 | 20,688 | 122,439 | 18,470 |
| 31 Dec 21 | 223,744 | 27,160 | 105,274 | 17,987 |
| 30 Sep 21 | 229,394 | 56,889 | 86,189 | 17,169 |
| 30 Jun 21 | 239,102 | 69,274 | 54,999 | 15,148 |
| 31 Mar 21 | 244,265 | 94,011 | 50,623 | 14,469 |
| 31 Dec 20 | 206,987 | 57,899 | 40,335 | 13,118 |
| 30 Sep 20 | 152,901 | 20,008 | 32,394 | 11,354 |
| 30 Jun 20 | 90,315 | 15,946 | 22,228 | 11,943 |
| 31 Mar 20 | 42,113 | -26,061 | 14,437 | 10,963 |
| 31 Dec 19 | 36,292 | -7,827 | 12,805 | 10,985 |
| 30 Sep 19 | 36,252 | -7,051 | 11,979 | 11,679 |
| 30 Jun 19 | 30,917 | -8,175 | 11,211 | 11,187 |
| 31 Mar 19 | 26,523 | -8,153 | 11,805 | 10,675 |
| 31 Dec 18 | 24,078 | -8,818 | 11,128 | 10,420 |
| 30 Sep 18 | 22,570 | -11,264 | 10,154 | 10,580 |
| 30 Jun 18 | 22,863 | -10,187 | 9,750 | 9,617 |
| 31 Mar 18 | 21,744 | -10,789 | 8,703 | 9,022 |
| 31 Dec 17 | 23,268 | -9,941 | 8,246 | 8,071 |
| 30 Sep 17 | 23,953 | -7,907 | 8,990 | 8,293 |
| 30 Jun 17 | 22,961 | -12,386 | 11,223 | 7,803 |
| 31 Mar 17 | 23,085 | -15,058 | 12,195 | 8,232 |
| 31 Dec 16 | 21,704 | -15,378 | 12,793 | 8,468 |
| 30 Sep 16 | 21,244 | -14,123 | 12,082 | 6,825 |
| 30 Jun 16 | 21,895 | -8,364 | 9,573 | 6,744 |
| 31 Mar 16 | 21,182 | -5,578 | 7,634 | 6,026 |
| 31 Dec 15 | 20,834 | -5,372 | 7,648 | 6,014 |
| 30 Sep 15 | 20,193 | -6,494 | 8,520 | 5,711 |
| 30 Jun 15 | 18,616 | -10,660 | 11,605 | 4,358 |
| 31 Mar 15 | 17,858 | -14,063 | 12,708 | 4,786 |
| 31 Dec 14 | 17,854 | -13,559 | 10,787 | 5,880 |
| 30 Sep 14 | 17,820 | -14,248 | 10,384 | 5,947 |
| 30 Jun 14 | 19,923 | -13,166 | 10,449 | 5,947 |
| 31 Mar 14 | 22,179 | -9,056 | 9,757 | 5,988 |
| 31 Dec 13 | 23,904 | -7,152 | 9,446 | 5,747 |
| 30 Sep 13 | 25,504 | -5,020 | 9,021 | 5,290 |
| 30 Jun 13 | 23,755 | -5,508 | 8,491 | 5,290 |
Quality Earnings: A064550 is currently unprofitable.
Growing Profit Margin: A064550 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A064550 is unprofitable, but has reduced losses over the past 5 years at a rate of 9.3% per year.
Accelerating Growth: Unable to compare A064550's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A064550 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A064550 has a negative Return on Equity (-2.95%), as it is currently unprofitable.